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abstract
PURPOSE To enable design of optimum palliative care for women with cervical cancer, we studied the most
common types of suffering and their severity, prevalence, and duration.
METHODS We first reviewed the literature on the major types, severity, prevalence, and duration of suffering
associated with cervical cancer. We then conducted a modified Delphi process with experts in cervical cancer
care to supplement the literature. For each type of suffering, we distinguished between decedents (those who
die from cervical cancer in a given year) and nondecedents (those who have cervical cancer in a given year but
do not die). By applying the suffering prevalence and duration estimates to the number of decedents, non-
decedents, and family caregivers in 2017, we were able to estimate their palliative care needs and the intensity of
palliative care needed to respond adequately to this suffering.
RESULTS There is a high prevalence among decedents of moderate or severe pain (84%), vaginal discharge
(66%), vaginal bleeding (61%), and loss of faith (31%). Among both decedents and nondecedents, there is a
high prevalence of clinically significant anxiety (63% and 50%, respectively), depressed mood (52% and 38%,
respectively), and sexual dysfunction (87% and 83%, respectively). Moderate or severe financial distress is
prevalent among decedents, nondecedents, and family caregivers (84%, 74%, and 66%, respectively). More
than 40% of decedents and nondecedents are abandoned by their intimate partners. Most patients experience
some combination of moderate or severe physical, psychological, social, and spiritual suffering. In total, 258,649
decedents and 2,558,857 nondecedents needed palliative care in 2017, approximately 85% of whom were in
low- and middle-income countries where palliative care is rarely accessible.
CONCLUSION Among women with advanced cervical cancer, suffering is highly prevalent and often severe and
multifaceted.
JCO Global Oncol 7:862-872. © 2021 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
INTRODUCTION
Cervical cancer, a preventable disease, is one of the
gravest threats to women’s well-being and lives
worldwide. It is the fourth most common cancer in
women globally and disproportionately afflicts the poor.
One woman dies from it every 2 minutes, and the
limited available data suggest that women with cervical
cancer typically experience suffering that is more
complex and severe than that caused by other serious
illnesses.1-4 To stop the unnecessary suffering and
death from cervical cancer, the WHO developed the
Global Strategy to Accelerate the Elimination of Cervical
Cancer as a Public Health Problem, which was adopted
by the 73rd World Health Assembly in August 2020.5
The strategy outlines a comprehensive roadmap to-
ward elimination within the current century that entails
achievement of the 90-70-90 targets associated with
threemain pillars of the strategy: (1) primary prevention
through human papilloma virus (HPV) vaccination, (2)
screening with high-precision tests and treatment of
precancerous lesions, and (3) management of invasive
cervical cancer, including palliative care. But while
palliative care is an essential part of comprehensive
cancer care, design and implementation of optimum
palliative care for women with cervical cancer requires
better understanding of the suffering it engenders.6
In this paper, we identify the most common and severe
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including patients and their primary family caregivers, most
of whom are poor and live in low- or middle-income
countries (LMICs) where access to palliative care re-
mains rare.7 We also identify the prevalence and duration of
this suffering using a method pioneered by the Lancet
Commission on Palliative Care and Pain Relief.8 Our hy-
pothesis was that moderate and severe suffering is more
prevalent and multifaceted among women with cervical
cancer than among people with other cancers or serious
illnesses.9
Epidemiology
The International Agency for Research on Cancer (IARC)
estimates that, in 2018, 570,000 women were diagnosed
with cervical cancer and 311,000 women died of it. More
than 85% of cases occurred in LMICs or among poor and
marginalized communities in high-income countries
(HICs), and it was the most common cause of cancer-
related death in sub-Saharan Africa.10 Globally, in 2018,
the average age at diagnosis of cervical cancer was 53
years, and the average age at death was 59 years. China
and India together had more than a third of the global
cervical cancer cases (106,000 in China and 97,000
in India) and deaths (48,000 in China and 60,000 in
India).10
Five-year survival for women with cervical cancer varies
widely by country income level (Fig 1). Although data on 5-
year survival are scant from low-income countries (LICs)
and lower-middle–income countries (L-MICs), it appears
that a minority of patients survive for 5 years in these
countries where 3.6 of the world’s 7.7 billion people
live.11,12 Available data indicate that 5-year survival in LICs
may range from 3% to 23%. The differences in survival are
due in part to the late diagnosis of cancer in these countries
and the lack of access to adequate treatment including
external beam radiotherapy and brachytherapy.13 Each
increase in disease stage at diagnosis is known to decrease
5-year survival.12,14 But even in HICs, more than a third of
patients die within 5 years.
Among cervical cancers, around 70% are squamous cell
carcinomas, 25%-30% of carcinomas are adenocarci-
nomas, and there is a small percentage of noncarcinomas.5
Almost all cervical carcinomas are associated with chronic
HPV infection, which is also associated with increased risk
of vaginal and vulvar cancer in women, penile cancer in
CONTEXT
Key Objective
Cervical cancer disproportionately afflicts the poor and appears to cause worse suffering than most other serious illnesses. We
studied the major types, prevalence, severity, and duration of suffering associated with cervical cancer as a necessary
prerequisite to designing optimum palliative care.
Knowledge Generated
Among women with cervical cancer in 2017, there was a high prevalence of moderate or severe pain, malodorous vaginal
discharge, vaginal bleeding, anxiety, depressed mood, sexual dysfunction, and financial distress, and more than 40%
experienced abandonment by intimate partners. Patients’ primary family caregivers also experienced psychosocial dis-
tress. More than 3 million patients and primary family caregivers needed palliative care in 2017, 85% of whom were in low-
or middle-income countries.
Relevance
Cervical cancer generates suffering that is highly prevalent, severe, and varied, especially among the global poor. It is medically
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FIG 1. Five-year survival with cervical
cancer of any stage (%) by country
income level. HIC, high-income coun-
try; LIC, low-income country; L-MIC,
low-middle–income country; U-MIC,
upper-middle–income country. Sengayi-
Muchengeti et al.12 Arbyn et al,10
Allemani et al,11 Hong et al,32 National
Cancer Institute,33 Cancer Australia,34
Canadian Cancer Society.35
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men, as well as anorectal cancer and oropharyngeal cancer
in both men and women. Additional risk factors for cervical
cancer include chronic immunosuppression, first- and
second-hand exposure to tobacco smoke, prolonged use of
oral contraceptives, increasing parity, as well as increased
numbers of sexual partners or a single sexual partner who
has multiple sexual partners. Women living with HIV in-
fection are at increased risk for chronic HPV infection and
are six times as likely to develop HPV-associated cervical
cancer compared with HIV-negative women.15 This ac-
counts in part for the high prevalence of cervical cancer in
sub-Saharan Africa.13 Use of highly active antiretroviral
therapy partially reduces the risk of HPV-associated
neoplasia.16
Prophylactic HPV vaccination, given before onset of sexual
activity, conveys almost 100% protection against HPV in-
fection with the subtypes covered by the vaccine. However,
as of 2020, less than a quarter of LICs and, 30% of L-MICs
have introduced the HPV vaccine into their national im-
munization schedules, while more than 85% of HICs have
done so.15 Screening for HPV-associated cervical neopla-
sia, followed by ablative or excisional treatment, has been
shown to decrease the incidence of invasive cervical
cancer. But striking disparities between countries of dif-
ferent income levels also exist in access to cervical cancer
screening, diagnosis, and treatment services. Combined
basic capacity for pathology, cancer surgery, radiotherapy,
and chemotherapy is accessible only in about 13% of LICs.
The other 87% of LICs lack one or more of these services.
METHODS
We first conducted a review of the literature on the major
types, prevalence, and duration of suffering because of
cervical cancer. We began with a PubMed search using the
search terms uterine cervical cancer suffering, uterine
cervical cancer pain, and uterine cervical cancer palliative
care. All English-, French-, and German-language papers
reporting quantitative or qualitative data on the types, se-
verity, prevalence, or duration of suffering associated with
cervical cancer, all meta-analyses of such reports, and all
reviews of these topics were used for the study. Similar
papers noted on the PubMed website and in the reference
list of the downloaded papers were also used. For each
paper, we also noted the World Bank country income
classification of the country or countries from which data
were obtained. All quantitative data on the types, severity,
prevalence, or duration of suffering associated with cervical
cancer were used to populate preliminary tables. In cre-
ating these tables, we adhered to the standard distinction in
the palliative care literature between four categories of
suffering: physical, psychological, social, and spiritual.
Although these categories of suffering cannot be clearly
distinguished in clinical practice, we do so heuristically
here to better understand the ways women with cervical
cancer suffer and thus what would constitute optimum
palliative care. When there was more than one study
reporting data on the prevalence or duration of any specific
type of suffering, we calculated a mean for use in the
preliminary tables.
In light of the dearth of quantitative data, especially from
LMICs, on the specific types of suffering within each
category and of prevalence and duration of each type of
suffering, we also convened an expert panel of experi-
enced providers of care for women with cervical cancer to
review, comment on, and supplement our literature re-
view. The expert panel consisted of two clinicians from
each of the six WHO regions and included 10 medical
doctors, one nurse, and one social worker. One member
was from an LIC, five were from L-MICs, four were from
upper-middle–income countries, and two were from high-
income countries. We used a two-round modified Delphi
Process to achieve consensus among members of the
expert panel for refining and completing the preliminary
tables on the types, prevalence, and duration of physical,
psychological, social, and spiritual suffering experienced
by women with cervical cancer and their primary family
caregivers.17 Whereas the first round of a standard Delphi
Process would have entailed asking each participant to
identify the most common and severe types of suffering
and their prevalence without providing any data or sug-
gestions, we modified the first round by providing par-
ticipants with the preliminary tables populated with
available data from the literature on the most common and
severe types of suffering, their prevalence, and their du-
ration, to help inform their responses. For each type of
suffering, we asked the participants to distinguish between
decedents (those who die from cervical cancer in a given
year) and nondecedents (those who have cervical cancer
in a given year but do not die). We also asked participants
to estimate the prevalence and duration of most types of
psychological, social, and spiritual suffering of primary
family caregivers.
To determine the total number of patients with cervical
cancer per year who have one or more types of moderate or
severe suffering and therefore require palliative care, we
began with data on the number of deaths from cervical
cancer in 2017 from the Institute for Health Metrics and
Evaluation (IHME), the total prevalence of cervical cancer
in 2017 from the IHME, and the 5-year prevalence data
from IARC.18,19 The number of nondecedents was calcu-
lated as the sum of all patients with cervical cancer within 5
years of diagnosis and 50% of patients who survived longer
than 5 years. We used the IHME data from 194 countries
and territories. For the 16 countries for which no data from
IARC were available, we imputed 5-year survival using the
average from each country’s World Bank income group. To
calculate the number of family caregivers with moderate or
severe psychological, social, or spiritual suffering and thus
in need of palliative care, we assumed that each decedent
had only one primary family caregiver at risk of some type of
suffering.
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By applying the suffering prevalence and duration esti-
mates from the modified Delphi Process to the calculated
number of decedents, nondecedents, and family care-
givers, we were able to estimate the number of decedents,
nondecedents, and family caregivers who experienced
each type of suffering in 2017. We then also estimated the
intensity of palliative care needed to respond adequately to
this suffering, measured as the number of days when
contact with a palliative care provider is needed either in
inpatient or outpatient settings or in the home, to apply the
essential package of palliative care recommended by WHO
and described elsewhere.6,20,21 We generated estimates of
the palliative care need by patients with cervical cancer and
their family caregivers globally, regionally, for each country,
and for each country income group.
RESULTS
The results of the modified Delphi Process are shown in
Table 1. Cervical cancer and its treatment result in an
average prevalence of pain among decedents that is higher
(mild 96%; moderate-severe 84%) than among patients
with any other illness that commonly generates a need for
palliative care, including malignant neoplasms in general.8
Nearly two thirds of decedents suffer from moderate or
severe malodorous vaginal discharge (66%) and vaginal
bleeding (61%). Among nondecedents, prevalence of mild
TABLE 1. Global Burden of Suffering Associated With Cervical Cancer, Measured by the Prevalence of Moderate or Severe Physical, Psychological, Social,
and Spiritual Suffering of Patients and Family Caregivers and by the Average Duration of Each Type of Suffering
Decedents Nondecedents Family Caregivers
Type of Suffering Prevalence (%) Duration (months) Prevalence (%) Duration (months) Prevalence (%) Duration (months)
Physical suffering
Pain (mild) 96 5 42 7 NA NA
Pain (moderate or severe) 84 4 30 4 NA NA
Dyspnea 16 1 6 1 NA NA
Fatigue 71 5 44 6 NA NA
Weakness 58 4 37 4 NA NA
Nausea or vomiting 26 1 20 2 NA NA
Diarrhea 11 1 20 3 NA NA
Constipation 37 4 28 4 NA NA
Incontinence of urine 23 2 28 4 NA NA
Incontinence of stool 17 2 20 3 NA NA
Malodorous vaginal discharge 66 5 49 4 NA NA
Bleeding 61 2 53 3 NA NA
Dry mouth 31 3 NA NA NA NA
Leg edema 39 3 22 5 NA NA
Psychological suffering
Anxiety or worry 63 5 50 8 51 7
Depressed mood 52 5 38 6 28 6
Post-traumatic stress disorder 28 3 27 5 14 3
Confusion or delirium 26 1 NA NA NA NA
Sexual dysfunction 87 6 83 11 NA NA
Complicated grief NA NA NA NA 11 7
Social suffering
Stigma and discrimination 52 4 39 8 13 4
Financial difficulties 84 6 74 9 66 9
Abandonment by intimate partner 46 5 41 9 NA NA
Spiritual suffering
Loss of meaning 49 4 27 5 12 4
Anger toward higher power 31 2 21 5 18 4
Belief higher power causing illness 26 3 20 5 17 4
Abbreviation: NA, not applicable.
Cervical Cancer-Associated Suffering and Palliative Care Needs
JCO Global Oncology 865
Downloaded from ascopubs.org by The Aga Khan University on July 15, 2021 from 058.027.240.066
Copyright © 2021 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
pain is 42%, moderate or severe pain 30%, moderate or
severe malodorous vaginal discharge 49%, and moderate
or severe vaginal bleeding 53%. These symptoms con-
tribute to a high prevalence of moderate or severe psy-
chological suffering among both decedents and
nondecedents, including anxiety (63% and 50%, re-
spectively), depressed mood (52% and 38%, respectively),
and sexual dysfunction (87% and 83%, respectively).
Moderate or severe financial distress also is highly prevalent
among decedents (84%) and nondecedents (74%) and it
affects nearly two thirds of family caregivers (66%). More
than half of the decedents and more than a third of non-
decedents feel stigmatized or socially isolated (52% and
39%, respectively), and more than 40% are abandoned by
their intimate partner (46% and 41%, respectively). Nearly
half of the decedents experience loss of meaning in life
(49%), and nearly one third suffer a loss of faith (31%).
Most patients experience some combination of moderate or
severe physical, psychological, social, and spiritual
suffering.
In total, more than 3million people needed palliative care in
2017 because of the effects of cervical cancer: 258,649
decedent women with cervical cancer, an equal number of
family caregivers, and 2,558,857 nondecedent women
with cervical cancer (Table 2). L-MICs and upper-
middle–income countries had the largest number of pa-
tients and family caregivers in need of palliative care, and
85% of people in need (more than 2.6 million) were in
LMICs. Among the seven World Bank regions, the East Asia
and Pacific region had the largest number of people
(patients and their primary family caregivers) in need of
palliative care (33% of the global total) followed by the
South Asia and sub-Saharan Africa regions (19% and 17%
of the global total, respectively). The number of people with
each common type of suffering because of cervical cancer
is shown in Table 3. Globally, nearly 1 million women with
cervical cancer suffered from moderate or severe pain in
2017, 85% of whom were in LMICs. More than 1.4 million
suffered from moderate or severe malodorous vaginal
discharge, 84% of whom were in LMICs. Nearly 2 million
women suffered from moderate or severe sexual dys-
function, and nearly 2 million patients and family caregivers
combined suffered from moderate or severe financial dif-
ficulties associated with the patient’s cervical cancer.
To provide adequate palliative care globally for women with
cervical cancer, in 2017, using the WHO essential package
of palliative care, we estimated that an inpatient palliative
care encounter would have been needed on 22,919 days,
an outpatient encounter on 34,586 days, and a home visit
on 35,038 days (Table 4). Of the total of 92,543 days when
a palliative care encounter would have been needed,
78,576 of these encounters (85%) were needed in LMICs.
DISCUSSION
To our knowledge, ours is the first quantitative study of the
major types, severity, prevalence, and duration of suffering
associated with cervical cancer. Our data indicate that
women with cervical cancer experience physical, psy-
chological, social, and spiritual suffering that is more
prevalent, complex, and severe than the suffering
TABLE 2. Number of Decedent and Nondecedent Women With Cervical Cancer, and Their Family Caregivers, Who Needed Palliative Care in 2017, by
Country Income Group and Region
Country Income Group or Region Decedents Nondecedents Family Caregivers People Needing PC—Total No. %
By country income groupa
Low (LICs) 34,065 268,377 34,065 336,508 11
Lower-middle (L-MICs) 96,741 912,766 96,741 1,106,247 36
Upper-middle (U-MICs) 91,998 973,446 91,998 1,157,443 38
High (HICs) 35,845 404,268 35,845 475,957 15
Global 258,649 2,558,857 258,649 3,076,155 100
L&MICs 222,805 2,154,589 222,805 2,600,198 85
By regiona
East Asia and Pacific 79,260 862,848 79,260 1,021,369 33
Europe and Central Asia 30,362 322,186 30,362 382,909 12
Latin America and The Caribbean 32,271 312,642 32,271 377,184 12
Middle East and North Africa 4,280 47,080 4,280 55,641 2
North America 8,431 101,475 8,431 118,336 4
South Asia 53,968 487,657 53,968 595,593 19
Sub-Saharan Africa 50,077 424,969 50,077 525,124 17
Abbreviations: HIC, high-income country; LMIC, low-middle–income country; L&MIC, low- and middle-income country; LIC, low-income country; PC,
palliative care; UMIC, upper-middle–income country.
aWorld Bank categories.
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associated with most other serious illness.8 As a result of
inadequate availability of primary prevention, early diag-
nosis and treatment of cervical cancer, and social problems
such as poverty and stigmatization, a disproportionate
percentage of patients with cervical cancer and family care
givers in need of palliative care live in LMICs. Yet, access to
palliative care to prevent and relieve this suffering also
remains rare in LMICs.
Cervical cancer typically leads tomultiple types of moderate
and severe suffering for a variety of anatomic, physiologic,
psychological, and social reasons. For purely anatomic
reasons, pain due to cervical cancer and its treatment is
more prevalent and severe than pain because of many
other cancers. The pelvic region is highly innervated, and
major nerves and nerve plexuses, including the sacral
plexus and inferior hypogastric plexus, are located in or
near the pelvis. Thus, invasive cervical cancer often injures
nerves by invasion or compression resulting in neuropathic
pain that is more difficult to control than nociceptive pain.22
Pelvic nerve injury and neuropathic pain also may result
from surgery. In addition, peripheral neuropathic pain is a
common adverse effect of paclitaxel and cisplatin, the
TABLE 3. Number of Decedent and Nondecedent WomenWith Cervical Cancer and Their Family Caregivers With Each Common Type of Moderate or Severe
Suffering in 2017, by Country Income Group and Region (in Thousands)
By Income Group By Region
Type of Suffering LICs LMICs UMICs HICs Global L&MICs EAP ECA LAC MENA NA SA SSA
Physical suffering
Pain (mild) 145 476 497 204 1,323 1,119 574 210 227 33 70 350 313
Pain (moderate or severe) 109 355 369 151 985 834 423 155 167 25 52 258 231
Dyspnea 22 70 73 30 195 165 84 31 33 5 10 51 46
Fatigue 142 470 494 203 1,310 1,106 578 212 228 34 71 350 313
Weakness 119 394 414 170 1,097 926 485 177 191 28 60 294 262
Nausea or vomiting 63 208 219 90 579 489 258 94 102 15 32 156 139
Diarrhea 57 193 205 85 540 455 246 90 97 14 31 148 132
Constipation 88 291 307 126 812 686 362 132 143 21 45 219 195
Incontinence of urine 83 278 294 121 776 655 350 128 138 21 44 211 188
Incontinence of stool 59 199 210 87 556 469 251 92 99 15 31 151 135
Malodorous vaginal discharge 154 511 538 222 1,425 1,203 634 232 250 37 78 383 342
Bleeding 152 506 533 220 1,412 1,192 630 230 249 37 78 381 339
Dry mouth 11 30 29 11 80 69 25 9 10 1 3 17 16
Leg edema 72 239 250 103 664 561 292 107 115 17 36 177 158
Psychological suffering
Anxiety or worry 173 567 592 243 1,574 1,331 684 250 270 40 84 416 372
Depressed mood 129 424 444 182 1,179 997 514 188 203 30 63 313 280
Post-traumatic stress disorder 87 287 301 124 800 675 354 129 140 21 44 214 191
Confusion or delirium 9 25 24 9 67 58 21 8 8 1 2 14 13
Sexual dysfunction 252 842 888 367 2,349 1,982 1,054 385 416 62 131 636 567
Complicated grief 4 11 10 4 28 25 9 3 4 0 1 6 6
Social suffering
Stigma and discrimination 127 419 439 181 1,166 985 514 188 203 30 63 312 278
Financial difficulties 250 821 858 353 2,282 1,929 997 365 394 58 123 606 541
Abandonment by intimate partner 126 419 441 182 1,168 986 523 191 206 31 65 316 281
Spiritual suffering
Loss of meaning 93 305 319 131 849 718 369 135 146 21 45 224 201
Anger toward higher power 73 239 250 102 664 562 288 106 114 17 35 175 157
Belief higher power causing illness 68 224 234 96 623 527 271 99 107 16 33 165 148
Abbreviations: EAP, East Asia and Pacific region; ECA, Europe and Central Asia; HIC, high-income country; LMIC, low-middle–income country; L&MIC,
low- and middle-income country; LAC, Latin America and Caribbean; LIC, low-income country; MENA, Middle East and North Africa; NA, North America;
SA, South Asia; SSA, sub-Saharan Africa; UMIC, upper-middle–income country.
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TABLE 4. Number of Days With a Palliative Care Provider Contact, Including Inpatient Days, Outpatient Encounters, and Home Visits, for Decedent and Nondecedent Women With Cervical Cancer and
Their Family Caregivers in 2017, by Country Income Group and Region (in Thousands)
Location
Average PC Contacts per Year
on Average
By Income Group By Region
Population in Need of
Palliative Care LIC LMIC UMIC HIC Global
L&
MICs EAP ECA LAC MENA NA SA SSA
Decedents Referral hospitala Inpatient PC days (15) 511 1,451 1,380 538 3,880 3,342 1,189 455 484 64 126 810 751
Outpatient PC encounters (5) 170 484 460 179 1,293 1,114 396 152 161 21 42 270 250
District hospital Inpatient PC days (14) 477 1,354 1,288 502 3,621 3,119 1,110 425 452 60 118 756 701
Outpatient PC encounters (6) 204 580 552 215 1,552 1,337 476 182 194 26 51 324 300
Community health
center
Inpatient PC days (0.25) 9 24 23 9 65 56 20 8 8 1 2 13 13
Outpatient PC encounters (4) 136 387 368 143 1,035 891 317 121 129 17 34 216 200
Home PC visits (84) 2,861 8,126 7,728 3,011 21,727 18,716 6,658 2,550 2,711 360 708 4,533 4,206
Nondecedents Referral hospitala Inpatient PC days (3) 805 2,738 2,920 1,213 7,677 6,464 2,589 967 938 141 304 1,463 1,275
Outpatient PC encounters (4) 1,074 3,651 3,894 1,617 10,235 8,618 3,451 1,289 1,251 188 406 1,951 1,700
District hospital Inpatient PC days (3) 805 2,738 2,920 1,213 7,677 6,464 2,589 967 938 141 304 1,463 1,275
Outpatient PC encounters (4) 1,074 3,651 3,894 1,617 10,235 8,618 3,451 1,289 1,251 188 406 1,951 1,700
Community health
center
Outpatient PC encounters (4) 1,074 3,651 3,894 1,617 10,235 8,618 3,451 1,289 1,251 188 406 1,951 1,700
Home PC visits (5) 1,342 4,564 4,867 2,021 12,794 10,773 4,314 1,611 1,563 235 507 2,438 2,125
Family caregivers Home PC visits (two for needed
bereavement support)
68 193 184 72 517 446 159 61 65 9 17 108 100
Total inpatient PC days 2,607 8,306 8,532 3,474 22,919 19,445 7,495 2,821 2,820 408 855 4,505 4,015
Total outpatient encounters 3,732 12,404 13,061 5,389 34,586 29,197 11,543 4,322 4,236 629 1,344 6,661 5,851
Total home PC visits 4,272 12,884 12,779 5,104 35,038 29,934 11,131 4,222 4,338 604 1,232 7,080 6,431
Total days with any PC contact 10,610 33,594 34,372 13,967 92,543 78,576 30,169 11,365 11,394 1,640 3,432 18,245 16,297
Abbreviations: EAP, East Asia and Pacific region; ECA, Europe and Central Asia; HIC, high-income country; LMIC, low-middle–income country; L&MIC, low- and middle-income country; LAC, Latin
America and Caribbean; LIC, low-income country; MENA, Middle East and North Africa; NA, North America; PC, palliative care; SA, South Asia; SSA, sub-Saharan Africa; UMIC, upper-middle–income
country.
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chemotherapeutic agents used most commonly to treat
cervical cancer. Radiotherapy to the pelvis may result in
chronic inflammatory or nociceptive pain from vaginitis,
cystitis, or proctitis as well as in sexual dysfunction, urinary
incontinence, and diarrhea. Obstructive nephropathy and
resultant end-stage kidney disease, common sequelae of
cervical cancer, may result in dyspnea, pruritus, or delirium
and may exacerbate edema and pain. Metal or hard plastic
percutaneous nephrostomy drains, used in some places,
severely limit patients’ mobility and may increase risk of
pain, leakage, dependence, and psychological distress.
Fatigue and problems with memory and concentration
often result from some combination of pain, chemotherapy,
kidney disease, and depressed mood.
The high prevalence of psychological and social suffering
among both decedents and nondecedents is due at least in
part to the emotionally powerful meanings associated with
the sex organs and sexual function, both of which are
injured or ablated by invasive cervical cancer or its treat-
ment. These meanings are informed by cultural values that
often demean women deemed to have an unpleasant
bodily odor and those whose sexual function does not
reflect the cultural norm.3,23 In some East Asian cultures, for
example, a young woman’s status in society and personal
identity may depend heavily on the ability to bear children,
which often is destroyed by cervical cancer or its
treatment.24 Women with both HIV infection and cervical
cancer may be doubly stigmatized and at highest risk for
psychological, social, or spiritual suffering.
WHO defines palliative care as care that improves the
quality of life of patients and their families facing the
problems associated with life-threatening illness, through
the prevention and relief of suffering by means of early
identification and impeccable assessment and treatment of
pain and other problems, physical, psychosocial and
spiritual.25 In our view, the essence of palliative care is
prevention and relief of suffering, and the problems as-
sociated with life-threatening illness also may occur with
non–life-threatening conditions. For example, women with
early-stage, curable cervical cancer may suffer from
abandonment, depression, or treatment-related acute pain,
and long-term cervical cancer survivors may suffer from
chronic pain. The specific types and severity of suffering
vary by geopolitical situation, socioeconomic conditions,
culture, and accessibility of disease prevention and
treatment.26 People in LMICs typically experience less
healthy social conditions and greater morbidity and mor-
tality than people in HICs, yet they typically have less access
to disease prevention, diagnosis, and treatment. Palliative
care should never be considered a substitute for these, but
it is imperative that palliative care be universally
accessible.26-28
Our measure of necessary palliative care intensity (days-
when-a-palliative-care-encounter-is-needed) refines the
measure used by the Lancet Commission on Palliative Care
and Pain Relief (days-in-palliative care).8 Some patients
may require a palliative care encounter every day, whereas
others may require only one encounter per month. By the
previous measure, a patient receiving palliative care once
per month for 1 year would have 365 days in palliative care
but only 12 days with a palliative care encounter. Thus,
days-in-palliative-care is an inaccurate measure of needed
palliative care intensity and is not useful for estimating
human resource needed. Days-with-a-palliative-care-
encounter is a more accurate and useful measure.
Our study has several limitations. First, our literature review
was limited to papers in English, French, and German that
reported quantitative or qualitative data on the types, se-
verity, prevalence, or duration of suffering associated with
cervical cancer. However, among the English-language
papers that met these criteria, 10 were from China and
four were from countries whose official language is
Spanish. In addition, our PubMed search revealed only five
such papers in the other four official languages of the
United Nations, three in Chinese, and one each in Russian
and Spanish. Furthermore, our expert panel included
members from countries whose official languages are
Russian, Spanish, Arabic, French, Farsi, and Vietnamese.
Thus, we believe that our research reflects the global sit-
uation. Our literature review revealed a large publication
bias in that the majority of data on the types, severity,
prevalence, and duration of suffering associated with
cervical cancer came from HICs, whereas the majority of
suffering patients are in LMICs. In addition, the studies
used various methods, and although we did not system-
atically review each published study for bias, some con-
tained various degrees of selection, recall, or other biases.
We addressed these problems by conducting a modified
Delphi process with an expert panel from each WHO region
and from countries of all income classifications. Delphi
studies themselves are limited in that they rely on expert
opinion. But, we believe our method produced the most
reliable data to date on the suffering of a highly vulnerable
population.
The scarcity of quantitative data on the suffering of women
in LMICs with cervical cancer and other gynecologic
cancers reflects a morally indefensible neglect of this
vulnerable population. Our study provisionally fills this
massive gap in knowledge with expert opinion, but rigorous
quantitative study of this palliative care need is crucial.8 As
with all studies of highly vulnerable and seriously ill patients,
short but clinically and ethically well-crafted, locally vali-
dated tools are needed to assess clinical outcomes of
patients who receive any type of palliative care and those
who do not. Although measures of outputs such as opioid
accessibility and palliative care training programs are
useful, they are never an adequate substitute for measures
of patient outcomes such as quality of life, degree of pain
control, or presence of depression. Because the specific
types and severity of suffering vary, studies in different
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settings are needed to guide development of optimum
palliative care services for any given population.6,20
Implementation science studies of integration of palliative
care into healthcare systems at all levels, as urged by WHO,
are necessary to make services for women with cervical
cancer more integrated and people-centred.29 In light of the
particularly high prevalence in this population of severe
pelvic pain, humiliating malodorous vaginal discharge,
anxiety, depression, sexual dysfunction, financial difficul-
ties, and spiritual distress, these problems should be the
focus of intensive research on optimum palliative care in
LMICs. Further research on task shifting to improve access
to mental health care, including treatment of depression
and PTSD in patients with cervical cancer and other serious
and severely troubling illnesses, is also needed.30,31
In conclusion, the suffering of women with advanced
cervical cancer, an illness mainly of the global poor, has
been largely ignored by scientific research. By reviewing
the available literature and supplementing it with expert
consensus, we found that the suffering of this population
appears to be more prevalent, severe, and multifaceted
than that associated with other cancers. Severe pelvic pain,
malodorous vaginal discharge, sexual dysfunction, psy-
chological distress, and financial insecurity are particularly
prevalent. The high burden of suffering borne by women
with cervical cancer makes it medically and morally im-
perative that there be universal access to HPV vaccination,
screening, and treatment and that appropriate, effective,
affordable, people-centered palliative care be integrated
into all levels of systems of care for women with cervical
cancer. This integration will require vigorous efforts from
researchers, public health officials, oncologists, gynecol-
ogists, and primary care providers and should be part of the
overall integration of palliative care into healthcare systems
that is indispensable for achievement of universal health
coverage.27
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11Université Episcopale d’Haiti, Port-au-Prince, Haiti, Faculté des
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Correa, Mamadou Diop, Annekathryn Goodman, Quach Thanh Khanh,
Dingle Spence, Cherian Varghese, Elena Fidarova
Administrative support: C. R. Beena Devi
Provision of study materials or patients: Khadidjatou Kane, Gauhar Afshan,
Raimundo Correa, Quynh Xuan Nguyen Truong, Maryam Rassouli
Collection and assembly of data: Eric L. Krakauer, Xiaoxiao Kwete,
Khadidjatou Kane, Nahla Gafer, Annette Hasenburg, Suresh Kumar,
Diana Nevzorova, Maryam Rassouli, Elena Fidarova
Data analysis and interpretation: Eric L. Krakauer, Xiaoxiao Kwete,
Khadidjatou Kane, Lisa Bazzett-Matabele, Sarah Byrne-Martelli,
Stephen Connor, C. R. Beena Devi, Annekathryn Goodman, Surbhi
Grover, Annette Hasenburg, Kelly Irwin, M. R. Rajagopal, Tom Randall,
Cristiana Sessa, Julie S. Torode, Ted Trimble, Elena Fidarova
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST
The following represents disclosure information provided by authors of
this manuscript. All relationships are considered compensated unless
otherwise noted. Relationships are self-held unless noted. I = Immediate
Family Member, Inst = My Institution. Relationships may not relate to the
subject matter of this manuscript. For more information about ASCO’s
conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.
org/go/authors/author-center.
Open Payments is a public database containing information reported by
companies about payments made to US-licensed physicians (Open
Payments).
Eric L. Krakauer
Employment: Inform Diagnostics, Foundation Medicine
Xiaoxiao Kwete
Employment: Yaozhi Co Ltd
Stock and Other Ownership Interests: Expat Inc
Research Funding: Roche
Patents, Royalties, Other Intellectual Property: My husband Patrick Kwete
has a granted patent called Personalized Medical Treatment Provision
Software (https://patents.google.com/patent/US20130080425A1/en)
Travel, Accommodations, Expenses: Expat Inc
Annette Hasenburg
Honoraria: AstraZeneca, Med Update, Pfizer, Roche, StreamedupGmbH,
Tesaro, MedConcept, LEO Pharma
Consulting or Advisory Role: PharmaMar, Tesaro, Roche, AstraZeneca,
LEO Pharma, GlaxoSmithKline/MSD
Travel, Accommodations, Expenses: AstraZeneca, MedConcept, Roche,
Streamedup!, Tesaro, MedUpdate, Pfizer
Cristiana Sessa
Consulting or Advisory Role: Basilea
Ted Trimble
Consulting or Advisory Role: Merck, GlaxoSmithKline, Inovio
Pharmaceuticals
Research Funding: Frantz Viral Therapeutics
No other potential conflicts of interest were reported.
ACKNOWLEDGMENT
For helpful comments on the manuscript, the authors thank Sally Agallo
Kwenda, Esther Cege-Munyoro, Lailatul Ferdous, Liliana de Lima, Rei
Haruyama, Kim Hulscher, Elizabeth Mattfeld, Anastasia Merzlyakova,
and Linda Van Le.
REFERENCES
1. Kim YJ, Munsell MF, Park JC, et al: Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol
139:553-558, 2015
2. Bates MJ, Mijoya A: A review of patients with advanced cervical cancer presenting to palliative care services at Queen Elizabeth Central Hospital in Blantyre,
Malawi. Malawi Med J 27:93-95, 2015
3. Maree JE, Holtslander L, Maree JE: The experiences of women living with cervical cancer in Africa: Ametasynthesis of qualitative studies. Cancer Nurs 10.1097/
NCC.0000000000000812 [epub ahead of print on March 24, 2020]
4. Fowler JM, Carpenter KM, Gupta P, et al: The gynecologic oncology consult: Symptom presentation and concurrent symptoms of depression and anxiety.
Obstet Gynecol 103:1211-1217, 2004
5. World Health Organization (WHO): World Health Assembly Adopts Global Strategy to Accelerate Cervical Cancer Elimination. WHO, 2020. https://www.who.int/
news-room/detail/19-08-2020-world-health-assembly-adopts-global-strategy-to-accelerate-cervical-cancer limination#:∼:text=The%20World%20Health%
20Assembly%20has,detected%20early%20and%20managed%20effectively
6. Krakauer EL, Kwete X, Verguet S, et al: Palliative care and pain control, in Jamison DT, Gelband H, Horton S, et al (eds): Disease Control Priorities. Improving
Health and Reducing Poverty, Volume 9 (ed 3). Washington, DC, World Bank, 2018, pp 235-246
7. Connor SR (ed): Global Atlas of Palliative Care (ed 2). London, UK, Worldwide Hospice Palliative Care Alliance. Geneva, Switzerland, World Health Organization,
2020
8. Knaul FM, Farmer PE, Krakauer EL, et al: Alleviating the access abyss in palliative care and pain relief: An imperative of universal health coverage. Lancet
391:1391-1454, 2018
9. Mishra K: Gynaecological malignancies from palliative care perspective. Indian J Palliat Care 17:S45-S51, 2011 (suppl)
10. Arbyn M, Weiderpass E, Bruni L, et al: Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health 8:e191-e203,
2020
11. Allemani C, Matsuda T, Di Carlo V, et al: Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025
patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023-1075, 2018
12. Sengayi-Muchengeti M, Joko-FruWY,Miranda-Filho A, et al: Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development
Index: A population-based registry study. Int J Cancer 147:3037-3048, 2020
13. Rudd P, Gorman D, Meja S, et al: Cervical cancer in southern Malawi: A prospective analysis of presentation, management, and outcomes. Malawi Med J
29:124-129, 2017
14. Grigsby PW, Massad LS, Mutch DG, et al: FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. Gynecol Oncol 157:639-643,
2020
Cervical Cancer-Associated Suffering and Palliative Care Needs
JCO Global Oncology 871
Downloaded from ascopubs.org by The Aga Khan University on July 15, 2021 from 058.027.240.066
Copyright © 2021 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
15. World Health Organization (WHO): Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. Geneva, Switzerland, World
Health Organization, 2020
16. Kelly H, Weiss HA, Benavente Y, et al: Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive
cervical cancer in women living with HIV: A systematic review and meta-analysis. Lancet HIV 5:e45-e58, 2018
17. Sackman H: Delphi Assessment: Expert Opinion, Forecasting, and Group Process. Santa Monica, CA, Rand Corporation, 1974
18. Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease Collaborative Network: Global Burden of Disease Study 2017 (GBD 2017) Results.
Seattle, WA, Institute for Health Metrics and Evaluation (IHME), 2018
19. International Agency for Research on Cancer (IARC): Cancer Today—IARC. Lyon, France, International Agency for Research on Cancer, 2018
20. World Health Organization (WHO): Integrating Palliative Care and Symptom Relief into Primary Health Care: A WHO Guide for Planners, Implementers and
Managers. Geneva, Switzerland, World Health Organization, 2018
21. Knaul FM, Farmer PE, Krakauer EL, et al: Technical Note and Data Appendix for “Alleviating the Access Abyss in Palliative Care and Pain Relief—An Imperative
of Universal Health Coverage: The Lancet Commission Report”. Miami, FL, University of Miami Institute for Advanced Study of the Americas, 2018
22. Rayment C, Hjermstad MJ, Aass N, et al: Neuropathic cancer pain: Prevalence, severity, analgesics and impact from the European Palliative Care Research
Collaborative–Computerised Symptom Assessment study. Palliat Med 27:714-721, 2012
23. Maree JE, Kaila I: Zambian women’s experiences and understanding of cervical cancer: A qualitative study. Int J Gynecol Cancer 24:1065-1071, 2014
24. Lau KL, Yim PHW, Cheung EYW: Psychiatric morbidity in Chinese women after cervical cancer treatment in a regional gynaecology clinic. East Asian Arch
Psychiatry 23:144-153, 2013
25. World Health Organization (WHO): WHO Definition of Palliative Care. 2002. https://www.who.int/cancer/palliative/definition/en/
26. Krakauer EL: Palliative care, toward a more responsive definition. in MacLeod RD, Block L (eds): Textbook of Palliative Care. Cham, Switzerland, Springer
Nature, 2019
27. World Health Organization (WHO): World Health Assembly Resolution 67.19: Strengthening of Palliative Care as a Component of Comprehensive Care
Throughout the Life Course. Geneva, Switzerland, World Health Organization, 2014
28. Shulman LN, Mpunga T, Tapela N, et al: Bringing cancer care to the poor: Experiences from Rwanda. Nat Rev Cancer 14:815-821, 2014
29. World Health Organization (WHO): Framework on Integrated, People-Centred Health Services. Geneva, Switzerland, World Health Organization, 2016
30. World Health Organization (WHO): Task Shifting: Rational Redistribution of Tasks Among Health Workforce Teams. Global Recommendations and Guidelines.
Geneva, Switzerland, World Health Organization, 2008
31. Weobong B, Weiss HA, McDaid D, et al: Sustained effectiveness and cost-effectiveness of the Healthy Activity Programme, a brief psychological treatment for
depression delivered by lay counsellors in primary care: 12-month follow-up of a randomised controlled trial. PLoS Med 14:e1002385, 2017
32. Hong S, Won YJ, Park YR, et al: Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 52:335-350, 2020
33. National Cancer Institute: Cancer Stat Facts: Cervical Cancer. https://seer.cancer.gov/statfacts/html/cervix.html
34. Cancer Australia: National Cancer Control Indicators. https://ncci.canceraustralia.gov.au/




872 © 2021 by American Society of Clinical Oncology
Downloaded from ascopubs.org by The Aga Khan University on July 15, 2021 from 058.027.240.066
Copyright © 2021 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
